Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Saudi viewers angry over apparent ban on World Cup streaming
Walmart shooting claims teen, young woman, father, mother
THE BEST BLACK FRIDAY DEAL YET (Ad)
Cuba's informal market finds new space on growing internet
Best Buy Proves Brick and Mortar is Here to Stay
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:CLVS

Clovis Oncology - CLVS Stock Forecast, Price & News

$0.35
+0.01 (+1.76%)
(As of 11/25/2022 08:57 PM ET)
Add
Compare
Today's Range
$0.32
$0.35
50-Day Range
$0.27
$1.30
52-Week Range
$0.23
$3.33
Volume
926,000 shs
Average Volume
8.73 million shs
Market Capitalization
$50.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Clovis Oncology MarketRank™ Forecast

Analyst Rating
Hold
1.50 Rating Score
Upside/​Downside
1,345.1% Upside
$5.00 Price Target
Short Interest
Bearish
21.23% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.56mentions of Clovis Oncology in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$8 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.65) to ($0.86) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.89 out of 5 stars

Medical Sector

779th out of 1,044 stocks

Pharmaceutical Preparations Industry

374th out of 510 stocks

CLVS stock logo

About Clovis Oncology (NASDAQ:CLVS) Stock

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Stock News Headlines

Clovis Oncology falls 55% on bankruptcy concerns
Why Is Clovis Oncology (CLVS) Stock Up Today?
See More Headlines
Receive CLVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter.

CLVS Company Calendar

Last Earnings
11/03/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/22/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CLVS
CUSIP
18946410
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+1,345.1%
Consensus Rating
Hold
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$-264,520,000.00
Net Margins
-189.37%
Pretax Margin
-189.68%

Debt

Sales & Book Value

Annual Sales
$148.76 million
Book Value
($2.15) per share

Miscellaneous

Free Float
138,577,000
Market Cap
$50.15 million
Optionable
Optionable
Beta
0.41

Key Executives

  • Mr. Patrick J. Mahaffy MA (Age 55)
    Co-Founder, Chief Exec. Officer, Pres and Exec. Director
  • Dr. Gillian C. Ivers-Read BScDr. Gillian C. Ivers-Read BSc (Age 64)
    Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations
  • Mr. Daniel W. Muehl CPA (Age 54)
    Sr. VP of Fin. and Principal Financial & Accounting Officer
  • Dr. Lindsey Rolfe BSc (Age 50)
    MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance
  • Mr. Corwin Dale Hooks (Age 51)
    Chief Commercial Officer and Sr. VP













CLVS Stock - Frequently Asked Questions

Should I buy or sell Clovis Oncology stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clovis Oncology in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CLVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CLVS, but not buy additional shares or sell existing shares.
View CLVS analyst ratings
or view top-rated stocks.

What is Clovis Oncology's stock price forecast for 2023?

2 brokerages have issued twelve-month target prices for Clovis Oncology's shares. Their CLVS share price forecasts range from $5.00 to $5.00. On average, they predict the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 1,345.1% from the stock's current price.
View analysts price targets for CLVS
or view top-rated stocks among Wall Street analysts.

How have CLVS shares performed in 2022?

Clovis Oncology's stock was trading at $2.71 at the start of the year. Since then, CLVS shares have decreased by 87.2% and is now trading at $0.3460.
View the best growth stocks for 2022 here
.

When is Clovis Oncology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023.
View our CLVS earnings forecast
.

How were Clovis Oncology's earnings last quarter?

Clovis Oncology (NASDAQ:CLVS) posted its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.08. The biopharmaceutical company earned $37.92 million during the quarter, compared to analysts' expectations of $38.73 million. During the same quarter in the previous year, the business posted ($0.89) earnings per share.

What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO?

12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Clovis Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA).

What is Clovis Oncology's stock symbol?

Clovis Oncology trades on the NASDAQ under the ticker symbol "CLVS."

Who are Clovis Oncology's major shareholders?

Clovis Oncology's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (7.04%), Renaissance Technologies LLC (1.52%), State Street Corp (0.49%), Pinnacle Associates Ltd. (0.43%), QVT Financial LP (0.00%) and Aristeia Capital LLC (0.00%). Insiders that own company stock include Daniel W Muehl, Gillian C Ivers-Read, Lindsey Rolfe, Paul Edward Gross, Thomas C Harding and Thomas C Harding.
View institutional ownership trends
.

How do I buy shares of Clovis Oncology?

Shares of CLVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Clovis Oncology's stock price today?

One share of CLVS stock can currently be purchased for approximately $0.35.

How much money does Clovis Oncology make?

Clovis Oncology (NASDAQ:CLVS) has a market capitalization of $50.15 million and generates $148.76 million in revenue each year. The biopharmaceutical company earns $-264,520,000.00 in net income (profit) each year or ($1.83) on an earnings per share basis.

How can I contact Clovis Oncology?

Clovis Oncology's mailing address is 5500 FLATIRON PARKWAY SUITE 100, BOULDER CO, 80301. The official website for the company is www.clovisoncology.com. The biopharmaceutical company can be reached via phone at 303-625-5000, via email at bburkart@clovisoncology.com, or via fax at 303-245-0360.

This page (NASDAQ:CLVS) was last updated on 11/28/2022 by MarketBeat.com Staff